Suspension of trading

Spexis AG Stock Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - 12:36:37 2025-03-19 EDT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
-0.31%+2.44%+41.97%-0.61% 80.23B
-1.02%-0.51%-2.54%+26.80% 50.69B
-3.10%-4.84%+9.26%+158.46% 46.87B
-0.74%+3.26%-49.46%-48.10% 46.34B
-0.39%+0.91%+55.50%-23.07% 31B
-0.52%+7.01%+137.24%-36.68% 25.28B
-0.30%-0.33%+39.46%+84.18% 24.36B
-1.42%-1.11%-2.29%+189.51% 20.81B
-1.83%-2.82%+61.91%+105.60% 16.08B
Average -1.07%+1.44%+20.22%+35.69% 37.96B
Weighted average by Cap. -1.02%+1.13%+24.82%+36.75%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B